Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy

Sexually Transmitted Infections

Volumn 75, Issue 4, 1999, Pages 218-224

  Kaufmann, Gilbert R ^a   Zaunders, John ^a   Cooper, David A ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Chemokines; Cytokines; HAART; HIV; Immune reconstitution; Opportunistic infections; T lymphocytes

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; T LYMPHOCYTE RECEPTOR;

DRUG EFFECT; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; MEMORY CELL; MORBIDITY; MORTALITY; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REMISSION; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0032874052     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.75.4.218     Document Type: Review

References (96)

1. 1 Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998;280:78-86.
2. 2 Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5.
3. 3 Chun TW, Engel D, Mizell SB, et al. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 1998;188:83-91.
4. 4 Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-300.
5. 5 Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
6. 6 Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337: 725-33.
7. 7 Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996;334:1011-7.
8. 8 Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
9. 9 Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 1998;280:35-41.
10. 10 Arno A, Ruiz L, Juan M, et al. Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years, AIDS 1998;12:697-704.
11. 11 Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999;340:1301-6.
12. 12 Kelleher AD, Carr A, Zaunders J, et al. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-9.
13. 13 Autran B, Carcelain G, Li T, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-16.
14. 14 Van Noesel CJ, Gruters RA, Terpstra FG, et al. Functional and phenotypic evidence for a selective loss of memory T cells in asymptomatic human immunodeficiency virus-infected men. J Clin Invest 1990;86:293-9.
15. 15 Roederer M, Dubs JG, Anderson MT, et al. CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995;95:2061-6.
16. 16 Ullum H, Ac L, Victor J, et al. Increased losses of CD4+CD45RA+ cells in late stages of HIV infection is related to increased risk of death: evidence from a cohort of 347 HIV-infected individuals. AIDS 1997;11:1479-85.
17. 17 Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation Nat Med 1994;4:208-14.
18. 18 Gray CM, Schapiro JM, Winters MA, et al. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Human Retroviruses 1998;14:561-9.
19. 19 Fleury S, de Boer RJ, Rizzardi GP, et al. Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Nat Med 1998;4:794-801.
20. 20 Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med 1999;5:83-9.
21. 21 Andersson J, Fehniger TE, Patterson BK, et al. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS 1998;12:F123-9.
22. 22 Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998;12:745-50.
23. 23 Kaufmann D, Pantaleo G, Sudre P, et al. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998;351:723-4.
24. 24 Faye A, Race E, Obry V, et al. Viral fitness in patients with discordant CD4 and plasma HIV RNA evolution following protease inhibitor failure. Abstract 331, 6th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 1999.
25. 25 Bouscarat F, Levacherclergeot M, Dazza MC, et al. Correlation of CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patients infected by human immunodeficiency virus type 1. AIDS Res Human Retroviruses 1996;12:17-24.
26. 26 Bouscarat F, Levacher M, Landman R, et al. Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy. AIDS 1998;12: 1267-73.
27. 27 Mosley RL, Styre D, Klein JR. Differentiation and functional maturation of bone marrow-derived intestinal epithelial T cells expressing membrane T cell receptor in athymic radiation chimeras. J Immunol 1990;145:1369-75.
28. 28 Sato K, Ohtsuka K, Hasegawa K, et al. Evidence for extrathymic generation of intermediate T cell receptor cells in the liver revealed in thymectomixed, irradiated mice subjected to bone marrow transplantation. J Exp Med 1995;182:759-67.
29. 29 Dejbakhsh-Jones S, Jerabek L, Weissman IL, et al. Extrathymic maturation of alpha beta T cells from hemopoietic stem cells. J Immunol 1995;155:3338-44.
30. 30 Bell EB, Sparshott SM, Drayson MT, et al. The stable and permanent expansion of functional T lymphocytes in athymic nude rats after a single injection of mature T cells. J Immunol 1987;139:1379-84.
31. 31 Rocha BB. Population kinetics of precursors of IL 2-producing peripheral T lymphocytes: evidence for short life expectancy, continuous renewal, and post-thymic expansion. J Immunol 1987;139:365-72.
32. 32 Rocha B, Dautigny N, Pereira P. Peripheral T lymphocytes: expansion potential and homeostatic regulation of pool sizes and CD4/CD8 ratios in vivo. Eur J Immunol 1989;19: 905-11.
33. 33 Mackall CL, Bare CV, Granger LA, et al. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol 1996;156:4609-16.
34. 34 Cohen Stuart JW, Slieker WA, Rijkers GT, et al. Early recovery of CD4+ T lymphocytes in children on highly active antiretroviral therapy. Dutch study group for children with HIV infections. AIDS 1998;12:2155-9.
35. 35 Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998;396:690-5.
36. 36 Walker RE, Carter CS, Muul L, et al. Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration in HIV-infected adults. Nat Med 1998;4:852-6.
37. 37 Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997;3:533-40.
38. 38 Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998;178:70-9.
39. 39 Martinon F, Michelet C, Peguillet I, et al. Persistent alterations in T-cell repertoire, cytokine and chemokine gene expression after 1 year of highly active antiretrovial therapy. AIDS 1999;13:185-91.
40. 40 Lane HC, Depper JM, Greene WC, et al. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med 1985;313:79-84.
41. 41 Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest 1989;84:1892-9.
42. 42 Miedema F, Petit AJ, Terpstra FG, et al. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest 1988;82:1908-14.
43. 43 Shearer GM, Clerici M. T helper cell immune dysfunction in asymptomatic, HIV-1-seropositive individuals: the role of TH1-TH2 cross-regulation. Chem Immunol 1992;54:21-43.
44. 44 Angel JB, Kumar A, Parato K, et al. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 1998;177:898-904.
45. 45 Chougnet C, Fowke KR, Mueller BU, et al. Protease inhibitor and triple-drug therapy: cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment. AIDS 1998;12:2397-406.
46. 46 Rinaldo C, Liebmann J, Huang X, et al. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis 1999;179:329-36.
47. 47 Autran B, Carcelain G, Tubiana R, et al. Effects of antiretoviral therapy on immune reconstitution. Abstract S44, 6th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 1999.
48. 48 Carcelain G, Tubiana R, Li TS, et al. Long-term recovery in CD4+ T cell function with highly efficient antiretroviral therapy. Abstract 324, 6th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 1999.
49. 49 Plana M, Garcia F, Gallart T, et al. Immunologic reconstitution after 12 months of antiretroviral therapy in very early stages of chronic HIV-1 infection. Abstract 323, 6th Conference, on Retroviruses and Opportunistic Infections, Chicago, USA, 1999.
50. 50 Plana M, Garcia F, Gallart T, et al. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study. Lancet 1998;352:1194-5.
51. 51 Li TS, Tubiana R, Katlama C, et. al. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-6.
52. 52 Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegulovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998; 4:953-6.
53. 53 Valdez H, Smith K, Lederman M, et al. Response to immunization with recall and neoantigen after 48 weeks of HAART. Abstract 329, 6th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 1999.
54. 54 Kelleher AD, Roggensack M, Emery S, et al. Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens. Clin Exp Immunol 1998;113:85-91.
55. 55 Goujard C, Taoufik Y, Wallon C, et al. HIV-1 specific CD4+ T cell response is not restored after 28 months of HAART with viral load < 50 copies/ml. Abstract 343, 6th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 1999.
56. 56 Pantaleo G, Graziosi C, Demarest JF, et al. Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. Immunol Rev 1994;140:105-30.
57. 57 Zhang ZQ, Schuler T, Cavert W, et al. Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. Proc Natl Acad Sci USA 1999;96:5169-72.
58. 58 Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103-6.
59. 59 Ogg GS, Jin X, Bonhoeffer S, et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999;73:797-800.
60. 60 Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1-specific CD4+ T cells are deteciable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999;5:518-25.
61. 61 Kroon FP, Rimmelzwaan GF, Roos MT, et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS 1998;12:F217-23.
62. 62 Hardy GAD, Imami N, Gazzard B, et al. Kinetics of lymphocyte proliferation, IL-2 and IL-4 production in HIV-1 infected individuals initiating HAART. Abstract 322, 6th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 1999.
63. 63 Imami N, Hardy GAD, Antonopoulos C, et al. Assessment of type-1 and type-2 cytokines in HIV-1 infected individuals: impact of highly active antiretroviral therapy. Abstract 333, 6th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 1999.
64. 64 Aukrust P, Muller F, Froland S. Circulating levels of RANTES in human immunodeficiency virus type 1 infection: effect of potent antiretroviral therapy. J Infect Dis 1998;177:1091-6.
65. 65 Zaunders J, Cunningham P, Kelleher A, et al. Potent antiretroviral therapy of primary HIV-1 infection: partial normalization of T lymphocyte subsets and limited reduction of proviral DNA despite clearance of plasma viremia. J Infect Dis (in press).
66. 66 Malhotra U, Berrey MM, Huang Y, et al. Effect of combination antiretoviral therapy on HIV-1 specific cellular immunity in acute HIV-1 infection. Abstract 23, 6th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 1999.
67. 67 Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-50.
68. 68 Connors M, Kovacs J, Krevat S. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997;3:533-40.
69. 69 Carr A, Emery S, Lloyd A, et al. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multi-center study. Australian IL-2 Study Group. J Infect Dis 1998;178:992-9.
70. 70 Hengge UR, Goos M, Esser S, et al. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS 1998;12:F225-34.
71. 71 Bartlett JA, Berend C, Petroni GR, et al. Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042. J Infect Dis 1998;178:1170-3.
72. 72 De Paoli P, Zanussi S, Simonelli C, et al. Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects. J Clin Invest 1997;100:2737-43.
73. 73 Fleming P, Ward J, Karon J, et al. Declines in AIDS incidence and deaths in the USA: a signal change in the epidemic. AIDS 1998;12:S55-61
74. 74 Walsh JC, Jones CD, Barnes EA, et al. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors. AIDS 1998;12:613-8.
75. 75 Jacobson MA, French M. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. AIDS 1998;12(Suppl A): S157-63.
76. 76 Mocroft A, Vella S, Benfield T, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-30.
77. 77 Goguel J, Katlama C, Sarfati C, et al. Remission of AIDS-associated intestinal microsporidiosis with highly active antiretroviral therapy. AIDS 1997;11:1658-9.
78. 78 Foudraine NA, Weverling GJ, van Gool T, et al. Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy. AIDS 1998; 12:35-41.
79. 79 Aberg JA, Yajko DM, Jacobson MA. Eradication of AIDS-related disseminated mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. J Infect Dis 1998;178:1446-9.
80. 80 Baqi M, Kucharczyk W, Walmsley SL. Regression of progressive multifocal encephalopathy with highly active antiretroviral therapy. AIDS 1997;11:1526-7.
81. 81 Carr A, Marriott D, Field A, et al. Treatment of HIV-1-associated microspondiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998;351: 256-61.
82. 82 Hood S, Bonington A, Evans J, et al. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. AIDS 1998;12:447-8.
83. 83 Elliot B, Aromin I, Gold R, et al. 2.5 Year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy. Lancet 1997;349: 850.
84. 84 Revankar SG, Sanche SE, Dib OP, et al. Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients. AIDS 1998;12:2511-3.
85. 85 Teofilo E, Gouveia J, Brotas V, et al. Progressive multifocal leukoencephalopathy regression with highly active antiretroviral therapy. AIDS 1998;12:44
86. 86 Power C, Nath A, Aoki FY, et al. Remmission of progressive multifocal leukoencephalopathy following splenectomy and antiretroviral therapy in a patient with HIV infection. N Engl J Med 1997;336:661-2.
87. 87 Miralles P, Berenguer J, Garcia de Viedma D, et al. Treatment, of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy. AIDS 1998;12:2467-72.
88. 88 Michelet C, Arvieux C, Francois C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998;12:1815-22.
89. 89 Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997;349:1443-5.
90. 90 Gilquin J, Piketty C, Thomas V, et al. Acute cytomegalovirus infection in AIDS patients with CD4 counts above 100 × 10″ cells/1 following combination antiretroviral therapy including protease inhibitors. AIDS 1997;11:1659-60.
91. 91 Race E, Adelson-Mitty J, Kriegel G. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998;351:252-5.
92. 92 Martinez E, Gatell J, Moran Y, et al. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin Infect Dis 1998;27:1510-3.
93. 93 Macdonald JC, Torriani FJ, Morse LS, et al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998;177:1182-7.
94. 94 Whitcup SM, Fortin E, Nussenblatt RB, et al. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinites. JAMA 1997;277:1519-20.
95. 95 Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998;177:1080-3.
96. 96 Schneider MM, Borleffs JC, Stolk RP, et al. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet 1999;353:201-3.